Psoriasis is a systemic inflammatory disease, which may increase the risk of other inflammatory, cardiovascular, and metabolic diseases, as is shown in the elevated levels of homocysteine, resistin, leptin, and pentraxin 3 as well as the reduced levels of the anti-inflammatory marker adiponectin in the psoriasis patients compared to the control group. Here, ADIPOQ is linked to Other metabolic disease.